Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer
Sponsor: Shandong Cancer Hospital and Institute
Summary
The investigators conduct this phase II study to evaluate safety and effectiveness of EGCG in patients with dysphagia. Swallowing-related dysphagia and pain scores were recorded using the numerical rating scale (NRS) daily . Barium meal radiography was utilized to measure the luminal size and the length of the lesion area both before and after a week of EGCG treatment. The scales are translated into Chinese and guides in Chinese are developed instructing how to use the scales and perform the assessments.
Official title: Efficacy and Safety of Epigallocatechin-3-gallate, an Important Polyphenolic That Originates From Tea, in Patients With Esophageal Squamous Cancer: A Phase II Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2024-04-22
Completion Date
2026-05-22
Last Updated
2024-05-03
Healthy Volunteers
No
Interventions
Epigallocatechin-3-gallate
Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
Locations (1)
Shandong Cancer Hospital
Jinan, Shandong, China